Fabrication methods and material features | Cells/Animals | Cell shape | M1 markers | M2 markers | Overall polarization | References |
---|---|---|---|---|---|---|
Layer-by-layer (PEEK surfaces, several tens of nanometers and 200–500 nm) | RAW 264.7, THP-1 and BMSCs Sprague Dawley rats | Spherical shape with a few pseudopodia | ↓IL-6, IL-1β ↓TNF-α ↓iNOS, nitric oxide (NO) | ↑CD206 ↑TGF-β1, BMP2 ↑VEGF | M2 | [103] |
Anodization (Alumina membranes, 15–200 nm) | RAW 264.7 and rat BMSCs | 0-100 nm: become rounder and less pseudopodia with increasing diameter 200 nm: a less rounded shape and more pseudopodia | ↓CD86, CD11c, CCR7 ↓IL-18, IL-1β, IL-6 ↓TNF-α ↓ROS (100, 200 nm) ↓iNOS ↓Oncostatin-M | ↑CD206 ↑IκB | M2, especially on larger sized nanopores | [105] |
PS sphere template scarification and TiO2 crystallization (90-5000 nm) | RAW 264.7 and BMSCs Sprague-Dawley rats | 90, 500 nm: abundant filopodia Micrometer scale: less cellular protrusion | ↓CCR7 ↓IL-1α, TNF-α (90, 500 nm) | ↑CD206 (90, 500 nm) ↑IL-4, IL-10 (90,500 nm) | M2 on 90, 500 nm | [19] |
Chemical etching (Ti, oxidizing solution, 20–22 nm) | U937 (human leukemia cells) | More rounded morphology with long filopodia | ↓IP10 (CXCL10) ↓MIP3α (CCL20) ↑MCP-1 (CCL2) ↓OPN ↓SPARC/ stabilin 1 (subtle change) | N/A | M2-like | [110] |
Anodization (TiZr alloy, 35 nm diameter and 3.2 μm length) | RAW 264.7 | more rounded and smaller spread areas | ↓TNF-α ↓MCP-1 (after LPS stimulation) | N/A | M2-like | [104] |
Anodization (Alumina membranes, 20 and 200 nm) | RAW 264.7 and NIH 3T3 BALB/C mice | 20 nm: round 200 nm: more elongated and flattened | ↑IL-13, IL-1β, IL-6, IL-9, IL-2 (200 nm) ↑ROS (200 nm) | N/A | M1-like on 200 nm | [106] |
Alkali-hydrothermal treatment (Ti, Ra = 0.45 ± 0.03 μm) | THP1 (human monocytic cells) | No difference compared to smooth Ti surfaces | No difference in the expression of CCR7 compared to smooth Ti surfaces | No difference in the expression of CD206 compared to smooth Ti surfaces | No difference compared to smooth Ti surfaces | [111] |